Effect of intraperitoneal administration of low-molecular-weight heparin on plasma tissue factor pathway inhibitor levels in CAPD patients

Demirkan F., Akarsu M., Sifil A., Tutucu K.

NEPHRON, cilt.91, sa.1, ss.162-163, 2002 (SCI-Expanded, Scopus) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 91 Sayı: 1
  • Basım Tarihi: 2002
  • Doi Numarası: 10.1159/000057620
  • Dergi Adı: NEPHRON
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.162-163
  • Anahtar Kelimeler: continuous ambulatory peritoneal dialysis, tissue factor pathway inhibitor, intraperitoneal low-molecular-weight heparin
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

We investigated the systemic effect of intraperitoneal low-molecular-weight heparin (LMWH) in continuous ambulatory peritoneal dialysis (CAPD) patients by measuring plasma total tissue factor pathway inhibitor (TFPI) levels, regarding the fact that the levels of plasma TFPI increases 2- to 4-fold after subcutaneous and intravenous administration of unfractioned heparin or LMWH. Eleven men and 6 women who had been on CAPD for 32 26 months and 15 healthy controls were included in the study. After administration of intraperitoneal enoksiparin in dialysate, plasma samples were obtained 4 h later. TFPI levels were significantly higher in CAPD patients (207.8+/-55 ng/ml) compared to the healthy subjects (72.5+/-29 ng/ml) (p<0.0001). Both TFPI levels (225.9&PLUSMN;47 vs. 207.8&PLUSMN;55 ng/ml) (p<0.54) and plasma factor Xa (anti-FXa assay) (0.097+/-0.14 vs. 0.093+/-0.16 U/ml) (p<0.54) levels did not show any statistical difference before and after intraperitoneal administration of LMWH. By these findings we might suggest that intraperitoneal LMWH does not have any systemic effect. Copyright (C) 2002 S. Karger AG, Basel.